There is significant interest in optimizing medical treatments of Crohn’s disease (CD) in hopes of preventing complications and the need for surgery.
Measurement of fecal volatile organic compounds (VOC) was effective in identifying inflammatory bowel disease (IBD) biomarkers, but not for monitoring disease activity.
Certain enteric pathogens are associated with higher risk of incident inflammatory bowel disease, while others are could be protective.
Higher infliximab trough levels were associated with clinical and endoscopic remission in patients with Crohn disease (CD), according to a substudy.
Adalimumab, an anti-Tumor Necrosis Factor alpha (TNFα) antibody, may be effective in managing inflammatory bowel disease symptoms in patients with COVID-19.
An international team of investigators conducted a follow-up to the CALM study to assess the impact of early disease remission in individuals with Crohn disease.
Older age is associated with an increased risk for bacteremia in hospitalized patients with inflammatory bowel disease.
Deep early remission of Crohn disease is associated with a significant decrease in long-term adverse effects.
A panel of serum biomarkers was found to identify patients who will develop Crohn disease up to 5 years before diagnosis.
In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.
This review examines the unique manifestations of inflammatory bowel disease (such as growth and pubertal delay), health maintenance issues, and treatment considerations in the adolescent.
There is insufficient evidence for recommending specific changes or restrictions of intake of fruit and vegetables in ulcerative colitis.
Emotions, cognitions, and behaviors are significantly associated with pain severity and pain-related interference in IBD, including pain-specific cognitions and behaviors.
The study examined the importance of confronting general dysfunctional beliefs, particularly notions of low self-efficacy and failure, in short-term therapy for patients with IBD.
An inflammatory bowel disease diagnosis conferred an increased risk for venous thromboembolism; however, in surgical patients, ulcerative colitis but not Crohn disease was responsible for the elevated risk.
There appears to be a link between hidradenitis suppurativa and inflammatory bowel disease.
Incidence of osteoporosis is significantly increased in patients with inflammatory bowel disease.
The risk of CKD in patients with inflammatory bowel disease is highest among young individuals.
In recent years, a number of preclinical models have shown that cannabinoids may be highly effective at improving inflammation and, therefore, may be a potential treatment for inflammatory bowel diseases.
Janssen announced interim data from the phase 3b STARDUST study of ustekinumab for the treatment of moderately to severely active Crohn disease.